Lonza officials reported the completion of the first GMP product batch supported from the recently completed next-generation mammalian manufacturing facility in Portsmouth, NH.
Small-scale bioreactors provide many advantages in terms of flexibility, including reduced initial capital investments and lower operational costs, which help mitigate volume forecasting challenges during product launches, according to Stefan Egli, head of the mammalian business unit, who added that leveraging advancements in process analytical technology, optimized production processes, and enhanced drug output, along with Lonza’s BLA services, provides customers with a reliable route to market for various molecule types.
The new facility also complements the existing commercial mammalian-derived product manufacturing at 6,000L and 20,000L scales provided from Portsmouth.
“This milestone is a testament to our commitment to delivering industry-leading manufacturing services to our customers, highlighting our continued efforts to support our customers’ needs across their product lifecycle and meet growing market demand for the launch scale,” continued Egli. “The new 2,000L asset will support small- to mid-volume products, such as innovative therapies targeting rare diseases, and provides the flexibility required for efficient product launches and sustainable lifecycle management across our manufacturing network.”
